Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Nov 2021

Zhang Yifan, Chen Yi, Yang Chen, Seger Nelly, Hesla Asle C, Tsagkozis Panagiotis, Larsson Olle, Lin Yingbo, Haglund Felix

Abstract excerpt

Chondrosarcomas are the second most common malignant bone tumor. Activating promoter mutations in telomerase reverse transcriptase (TERT) was recently described by us and others as a frequent mutation in high-grade chondrosarcoma. In this study, we investigate the prognostic significance of TERT promoter mutations in 241 chondrosarcomas from 190 patients collected over 24 years (1994-2017). The TERT promoter was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Chondrosarcoma

Share to Disease Progression

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 34108637
DOI: 10.1038/s41379-021-00848-0
PMCID: PMC8514332

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.PMID 34108637Read ↗

hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.Semantic proximity Read ↗

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.Semantic proximity Read ↗

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read ↗

Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity Read ↗

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.Semantic proximity Read ↗

TERT promoter mutations and prognosis in solitary fibrous tumor.Semantic proximity Read ↗

A Genetic Model for Central Chondrosarcoma Evolution Correlates with Patient OutcomeSemantic proximity Read ↗

BRAF and TERT promoter mutations: clinical application in thyroid cancer.Semantic proximity Read ↗

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.Semantic proximity Read ↗

TERT promoter mutations in thyroid cancer.Semantic proximity Read ↗

TERT promoter mutations in solitary fibrous tumour.Semantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.